Changzhou Qianhong Biopharma Co Ltd Total Liabilities
Changzhou Qianhong Biopharma Co Ltd total liabilities. Based on the latest financial reports, Changzhou Qianhong Biopharma Co Ltd (002550) has total liabilities worth CN¥379.82 Million CNY (≈ $55.58 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002550 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Changzhou Qianhong Biopharma Co Ltd (2007–2025)
Total liabilities of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025. This chart illustrates how Changzhou Qianhong Biopharma Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Changzhou Qianhong Biopharma Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Changzhou Qianhong Biopharma Co Ltd Competitors by Total Liabilities
The table below lists competitors of Changzhou Qianhong Biopharma Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tennant Company
NYSE:TNC
|
USA | $735.60 Million |
|
Zhejiang Dayuan Pumps Ind Co
SHG:603757
|
China | CN¥766.99 Million |
|
Dole plc
F:4CB
|
Germany | €2.89 Billion |
|
Genusplus Group Ltd
AU:GNP
|
Australia | AU$580.83 Million |
|
Xinjiang Machinery Research Inst
SHE:300159
|
China | CN¥553.44 Million |
|
Bonheur
OL:BONHR
|
Norway | Nkr15.88 Billion |
|
JM Financial Limited
NSE:JMFINANCIL
|
India | Rs-113.58 Billion |
|
Genius Sports Ltd
NYSE:GENI
|
USA | $322.57 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Changzhou Qianhong Biopharma Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Changzhou Qianhong Biopharma Co Ltd (002550) total assets.
Liquidity & Leverage Metrics
Changzhou Qianhong Biopharma Co Ltd Total Liabilities Ratios Explained
Changzhou Qianhong Biopharma Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Changzhou Qianhong Biopharma Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Changzhou Qianhong Biopharma Co Ltd (2007–2025)
The table below shows the annual total liabilities of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥320.64 Million ≈ $46.92 Million |
+2.16% |
| 2024-12-31 | CN¥313.87 Million ≈ $45.93 Million |
+7.43% |
| 2023-12-31 | CN¥292.17 Million ≈ $42.75 Million |
-21.57% |
| 2022-12-31 | CN¥372.53 Million ≈ $54.51 Million |
-4.54% |
| 2021-12-31 | CN¥390.24 Million ≈ $57.10 Million |
+1.01% |
| 2020-12-31 | CN¥386.35 Million ≈ $56.54 Million |
-35.78% |
| 2019-12-31 | CN¥601.65 Million ≈ $88.04 Million |
-6.01% |
| 2018-12-31 | CN¥640.11 Million ≈ $93.67 Million |
+8.24% |
| 2017-12-31 | CN¥591.41 Million ≈ $86.54 Million |
-2.94% |
| 2016-12-31 | CN¥609.33 Million ≈ $89.16 Million |
+13.12% |
| 2015-12-31 | CN¥538.67 Million ≈ $78.82 Million |
+202.52% |
| 2014-12-31 | CN¥178.06 Million ≈ $26.06 Million |
+85.94% |
| 2013-12-31 | CN¥95.77 Million ≈ $14.01 Million |
+63.58% |
| 2012-12-31 | CN¥58.54 Million ≈ $8.57 Million |
-32.76% |
| 2011-12-31 | CN¥87.07 Million ≈ $12.74 Million |
-35.38% |
| 2010-12-31 | CN¥134.75 Million ≈ $19.72 Million |
-53.56% |
| 2009-12-31 | CN¥290.19 Million ≈ $42.46 Million |
+67.01% |
| 2008-12-31 | CN¥173.75 Million ≈ $25.43 Million |
+125.79% |
| 2007-12-31 | CN¥76.95 Million ≈ $11.26 Million |
-- |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more